{
  "authors": [
    {
      "author": "Yu Qiao"
    },
    {
      "author": "Jihong Yang"
    },
    {
      "author": "Lili Liu"
    },
    {
      "author": "Yixin Zeng"
    },
    {
      "author": "Jie Ma"
    },
    {
      "author": "Jing Jia"
    },
    {
      "author": "Li Zhang"
    },
    {
      "author": "Xiaoguang Li"
    },
    {
      "author": "Peihong Wu"
    },
    {
      "author": "Wenchao Wang"
    },
    {
      "author": "Dongge Liu"
    },
    {
      "author": "Huan Chen"
    },
    {
      "author": "Yunbo Zhao"
    },
    {
      "author": "Huan Xi"
    },
    {
      "author": "Yao Wang"
    }
  ],
  "doi": "10.1186/s12885-018-3996-3",
  "publication_date": "2018-02-23",
  "id": "EN113505",
  "url": "https://pubmed.ncbi.nlm.nih.gov/29466964",
  "source": "BMC cancer",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15Â months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor."
}